The Food and Drug Administration Friday announced that it had approved Rapamune (sirolimus), distributed by Pfizer’s Wyeth Pharmaceuticals, as a treatment for the rare lung disease lymphangioleiomyomatosis (LAM).
The AARP Public Policy Institute’s latest Rx Price Watch Report shows that, despite an overall 4% decrease in price in 2013, the prices of generic drugs seem to be dropping at the slowest rate since 2006.
Mergers and acquisitions among pharmaceutical companies has kicked into high gear this year, mirroring the larger trend sweeping across the entire spectrum of the health care industry since the implementation of the Affordable Care Act two years ago.
Taiwan-based drug development company Sunny Pharmtech and Vitruvias Therapeutics, a generic drug development company, on Tuesday announced that they will team up to co-develop a portfolio of generic drug products.
Actavis last week announced that its acquisition of Allergan has been completed in a transaction valued at $70.5 billion, a deal that creates one of the world’s top 10 pharmaceutical companies by sales revenue, according to the company.
Impax Labs completed its acquisition of Tower Holdings (which includes operating subsidiaries CorePharma and Amedra Pharmaceuticals), and Lineage Therapeutics. Impax also announced that it would reshape both the operating and reporting structure of its two divisions.